Enrique Chacon-Cruz: Thrombocytopenia and ITP Risk After Vaccination
Enrique Chacon-Cruz, Member, Health Equity Committee at European Society of Medicine, Chief Editor of Vaccines Beat, shared a post on LinkedIn about a recent article by Matthew Z. Dudley et al., published in Vaccine, adding:
“Incidence, risk factors, and association with vaccination of thrombocytopenia and immune thrombocytopenia (ITP): A scoping review.
Dudley MZ, Ali H, Villaescusa MR, Law B.
Thrombocytopenia is a rare event with multiple potential causes, making careful assessment essential when evaluating vaccine safety signals.
This updated Brighton Collaboration review found background incidence estimates ranging widely from 1.6 to 92.1 cases per 100,000 person-years and identified numerous non-vaccine risk factors.
Evidence consistently supports an increased risk of immune thrombocytopenia (ITP) following measles-containing vaccines, while several studies also identified increased risk after adenoviral COVID-19 vaccines.
In contrast, most studies found no association with other vaccines, including mRNA and inactivated COVID-19 vaccines.
These findings reinforce the importance of standardized case definitions and consideration of background risk when assessing adverse events following immunization.”
Title: Incidence, risk factors, and association with vaccination of thrombocytopenia and immune thrombocytopenia (ITP): A scoping review
Authors: Matthew Z. Dudley, Hammad Ali, Marta Rojo Villaescusa, Barbara Law
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 15, 2026, 23:35Katya McCarthy: From Lab Specialist to Patient – Facing Polycythemia and Venous Thrombosis
-
Sep 15, 2026, 23:19Narat Srivali: Chronic Preoperative Corticosteroid Use Associated with 51% Higher Postoperative VTE Risk
-
Sep 15, 2026, 23:13Grace M Thomas: Join 3rd edition of the Neutrophil Club of SFI Webinar Series on Thromboinflammation
-
Sep 15, 2026, 23:05Noha K Hashmi: Honoured to Present 2 Case-Based Posters at the 5th MENA Conference for Rare Diseases 2026
-
Sep 15, 2026, 22:56Susan Slingluff Hartmann: How NBDF and the BDRC Are Putting Lived Experience at the Heart of Studies
-
Sep 15, 2026, 22:50Shehab Mohamed: New GCC Consensus Recommendations for the Diagnosis and Management of HLH
-
Sep 15, 2026, 22:42100 Years of von Willebrand Disease: What Has a Century of Progress Taught Us? – EAHAD
-
Sep 15, 2026, 22:38Cedric Hermans: How Iis TFPI Inhibition Changing Haemophilia Care?
-
Sep 15, 2026, 17:33Reza Shojaei: Blood and Plasma Donors Are Not a Production Metric